Title :

Affron (R) and increase in positive mood: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Author(s) :

Turck, Dominique [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Castenmiller, J. [Auteur]
European Food Safety Authority [EFSA]
De Henauw, S. [Auteur]
Hirsch-Ernst, K. I. [Auteur]
Kearney, J. [Auteur]
Knutsen, H. K. [Auteur]
Maciuk, A. [Auteur]
Mangelsdorf, I. [Auteur]
Mcardle, H. J. [Auteur]
Naska, A. [Auteur]
Pelaez, C. [Auteur]
Pentieva, K. [Auteur]
Thies, F. [Auteur]
Tsabouri, S. [Auteur]
Vinceti, M. [Auteur]
Bresson, J. L. [Auteur]
Siani, A. [Auteur]

Journal title :

EFSA Journal

Abbreviated title :

EFSA J.

Volume number :

19

Pages :

-

Publication date :

2021-07-21

ISSN :

1831-4732

English keyword(s) :

affron (R)
saffron
crocins
safranal
mood
anxiety
health claim

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Following an application from Pharmactive Biotech Products, S.L. submitted for authorisation of ahealth claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority ofSpain, the EFSA Panel ...
Show more >Following an application from Pharmactive Biotech Products, S.L. submitted for authorisation of ahealth claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority ofSpain, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver anopinion on the scientific substantiation of a health claim related to affron®and contributes to maintaina healthy mood. The scope of the application was proposed to fall under a health claim based onnewly developed scientific evidence. The food proposed by the applicant as the subject of the healthclaim is affron®, an aqueous saffron extract with a content of the sum of crocins and safranal typicallybetween 3.5% and 3.9%. The Panel notes that affron®is sufficiently characterised. The claimed effectproposed by the applicant is‘contributes to maintain a healthy mood’. The Panel notes that increase inpositive mood is a beneficial physiological effect for individuals with low mood or anxiety. One humanintervention study showed that consumption of affron®at a dose of 28 mg/day for 4 weeks improvesmood in a population of adults with low mood. However, the results have not been replicated in otherstudies. The information supplied by the applicant did not provide evidence for a plausible mechanismby which affron®could exert the claimed effect. The Panel concludes that the evidence is insufficientto establish a cause and effect relationship between the consumption of affron®and increase inpositive mood.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T06:27:35Z
2024-02-28T12:49:15Z